Research & Policy

At Biogen, we are committed to putting the weight of our business, our employees, and our collaboration partners to help close the disparity gap in clinical trials and access to healthcare.

Learn more about how we #BackTheFrontline by investing in innovators developing scalable solutions to COVID-19 from Johnson & Johnson Impact Ventures Chair Joe Wolk.

On July 1, Johnson & Johnson announced that the European Commission (EC) has granted Marketing Authorisation for its Janssen Pharmaceutical Companies’ Ebola vaccine regimen for the prevention of Ebola Virus Disease.

Two months after launching the Tomorrow Rising fund to support Covid-19 emergency relief in April 2020, Schneider Electric’s Foundation moves forward to support recovery and resiliency through education and training programs.

From concerns around vote hacking to the fear of exposure to COVID-19, states are under increased scrutiny about how they will handle this year’s election. There is one thing that provides a good solution for both concerns – paper.

After receiving the green light from the FDA to move forward, Gilead is about to start trials of an inhaled version of remdesivir. We will screen healthy volunteers for Phase 1 trials this week and hope to begin studies in patients with COVID-19...

Along with the Society for Immunotherapy of Cancer we strive for a future #Immune2Cancer because to our team, cancer immunotherapy research is personal.

BSR has developed three primers on how to respect human rights during the COVID-19 crisis: one for the energy and extractives sector; one for the food, beverage, and agriculture sector; and one for the transportation and logistics sector.

According to a study from Tork on the impact of COVID-19 on people’s perception of public hygiene, 86% believe keeping a high hygiene standard in public restrooms is critical to public safety.

Connecting our communities with accurate, in-depth information has never been more important than it is now and will be in the days to come.